Mike DiFiore (Evercore ISI)

Focus Areas3 topics

Innovation & R&D1Competitive Dynamics1Product Launch1

Trends2 quarters

Questions per Quarter

Questions

Challenging

Companies Covered

Question History2 questions

AMGNAmgen Inc.1 quarter

2025 Q3

There is some confusion on whether we'll get two-year weight loss data in the upcoming Part 2 readout of the MariTide obesity Phase II trial.

BIIBBiogen1 quarter

2025 Q1

has Biogen and Eisai perhaps paved the way for Lilly in terms of opening up healthcare infrastructure

Competitive DynamicsProduct LaunchView in transcript →